An internal standard for the quantification of flufenamic acid
Related Products
Unlabeled Version(s)
21447Flufenamic Acid
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Flufenamic Acid-d4

Item No. 33272

Technical Information
Formal Name
2-[[3-(trifluoromethyl)phenyl]amino]-benzoic acid-d4
CAS Number
1185071-99-1
Synonyms
  • FFA-d4
  • Fluphenamic Acid-d4
Molecular Formula
C14H6D4F3NO2
Formula Weight
Purity
≥99% deuterated forms (d1-d4)
Formulation
A solid
DMF: solubleDMSO: solubleMethanol: soluble
SMILES
OC(C(C([2H])=C([2H])C([2H])=C1[2H])=C1NC2=CC(C(F)(F)F)=CC=C2)=OOC(C(C([2H])=C([2H])C([2H])=C1[2H])=C1NC2=CC(C(F)(F)F)=CC=C2)=O
InChi Code
InChI=1S/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)/i1D,2D,6D,7D
InChi Key
LPEPZBJOKDYZAD-ZEJCXXMWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Flufenamic acid-d4 is intended for use as an internal standard for the quantification of flufenamic acid (Item No. 21447) by GC- or LC-MS. Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 3 and 9.3 µM for human COX-1 and COX-2, respectively).1 Flufenamic acid inhibits TNF-α-induced increases in COX-2 levels and NF-κB activation in HT-29 colon cancer cells in a concentration-dependent manner.2 It inhibits calcium influx induced by fMLP (fMLF; Item No. 21495) or A23187 (Item No. 11016) in human polymorphonuclear leukocytes (PMN) with IC50 values of 29 and 14 µM, respectively.3 Flufenamic acid also activates various ion channels, including transient receptor potential canonical 6 (TRPC6) and the large-conductance calcium-activated potassium channel (KCa1.1).4 It also inhibits various ion channels, including TRPC3 and the cystic fibrosis transmembrane conductance regulator (CFTR). Flufenamic acid (20 mg/kg) reduces increases in intestinal fluid secretion and intestinal barrier disruption in mice infected with the El Tor variant of V. cholerae.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Warner, T.D., Giuliano, F., Vojnovic, I., et alNonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc. Natl. Acad. Sci. USA 96(13), 7563-7568 (1999).

    2. Paik, J.H., Ju, J.H., Lee, J.Y., et alTwo opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase. Mediation through different signaling pathways. The Journal of Biological Chemisty 275(36), 28173-28179 (2000).

    3. Kankaanranta, H., and Moilanen, E. Flufenamic and tolfenamic acids inhibit calcium influx in human polymorphonuclear leukocytes. Mol. Pharmacol. 47(5), 1006-1013 (1995).

    4. Guinamard, R., Simard, C., and Del Negro, C. Flufenamic acid as an ion channel modulator. Pharmacol. Ther. 138(2), 272-284 (2013).

    5. Pongkorpsakol, P., Satitsri, S., Wongkrasant, P., et alFlufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. Eur. J. Pharmacol. 798, 94-104 (2017).